New hope for hard-to-treat breast cancer? olaparib trial begins
NCT ID NCT05522491
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests the drug olaparib in 30 women with recurrent or metastatic triple-negative breast cancer that has a specific DNA change (BRCA1 promoter methylation) but no BRCA gene mutation. Participants take olaparib pills until the disease worsens or side effects become too severe. The main goal is to see how many patients' tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- olaparib
- What this could lead to
- If it works, this could offer a new treatment option for a hard-to-treat breast cancer type that lacks common genetic mutations.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply widely. The drug may not shrink tumors or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRCA1 PROMOTER METHYLATED RECURRENT AND METASTATIC TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a new PET tracer reveal a key cancer target?
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new tracer light up cancer growth?
- Can a Dual-Pronged antibody outsmart advanced cancers?